85 results about "Hederagenin" patented technology

The present invention provides triterpenoids produced from natural compounds such as oleanolic acid, ursolic acid, betulinic acid, and hederagenin.

The invention relates to a hederagenin and a preparation method and purposes thereof. The compound is that the hederagenin is distilled from Nigella glandulifera freyn by degreasing, leaching and macroporous resin absorption, a structure of the hederagenin is confirmed by using physico-chemical constants, spectra database and single crystal method of X-ray diffractometry, the distilled hederagenin is proved in vitro to have the effect of tyrosine protein phosphatase PTP1B retardant and purposes as anti-diabetes drugs and health care products, meanwhile, the hederagenin is also applicable to be combination of drugs made from the compound or derivatives of the compound.

The present invention is a method for preparing triterpenoids such as 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester and derivatives thereof from oleanic acid, ursolic acid, betulinic acid, sumaresinolic acid or hederagenin.

A dipsacus root total saponin is disclosed in the present invention, its weight percent accounts for 60 percent to 95 percent of dipsacus root medicinal materials extraction gross, and in dipsacus root total saponin 3-O-alpha-L-arabinopyranosyl-hederagenin-28-O-beta-D-glucopyranosyl(1-6)-beta-D-glucopyranoside accounts for 30 percent to 90 percent of dipsacus root medicinal materials extraction. A dipsacus root extracting method and its application in preparing medicine for treating cervical vertebra, arthritis, hyperosteogeny or osteoporosis are also disclosed in the present invention. By researching pharmacologic effect of the dipsacus root total saponin, finding that the dipsacus root total saponin prepared by the present invention has obvious anti-inflammation, pain-relieving, increasing carotid blood flow and decreasing blood viscosity, treating oestrogen deficiency type osteoporosis function, and has obvious prevention and cure for experimental cervical spondylosis, arthritis, hyperosteogeny or osteoporosis.

The present invention relates to a novel purpose of hederagenin and a derivative of the hederagenin. An anti-depression test of the hederagenin and the derivative of the hederagenin shows obvious anti-depression activity, wherein, the salt derivative of the hederagenin has stronger anti-depression activity than the hederagenin; the hederagenin has stronger anti-depression activity than hederangenoside; the activities of the hederagenin and a hypericum extract are equivalent; sodium hederagenin has higher activity than the hypericum extract. The present invention has obvious pharmacological effect and stable quality; the raw material of the present invention has abundant source and cheap price and is safe with low toxin; the present invention has simple preparation technology and high yield, which provides novel medicine source for preventing, diagnosing, examining, protecting, remedying and researching on the depression and diseases directly related to the depression, is fit for the industrialization production, is easy for popularizing and applying and has very important value for developing and using Chinese officinal plant resource. Affective mental disorder is listed at top in Chinese disease general burden, and the research and manufacture of the drug for preventing and remedying the depression has obvious social benefit and economic benefit.

The invention relates to a method for preparing a pulsatilla chinensis (Bunge) Regel saponin matter and application of the pulsatilla chinensis (Bunge) Regel saponin matter in preparation of an antischistosomal medicament. The pulsatilla chinensis (Bunge) Regel saponin matter is a single-component compound, and the method for preparing the pulsatilla chinensis (Bunge) Regel saponin matter comprises the following steps of: grinding the pulsatilla chinensis (Bunge) Regel medicinal materials into coarse powder, soaking by using ethanol, performing reflux extraction, condensing and drying, collecting dry extract, dissolving the dry extract in water, performing macroporous resin adsorption, and collecting the ethanol eluation part; and treating by using an opposite phase silica gel column, and collecting the eluation part of methanol and water to obtain the single-component compounds. According to the comparison with a comparison product and the LC / MS / MS test, the compounds are 3-O-alpha-L-rhamnopyranosyl-(1-2)-alpha-L-arabinopyranosyl-hederagenin28-O-alpha-L-rhamnopyranosyl-(1-4)-beta-D-glucopyranose-(1-6)-beta-D-glucopyranoside.

The invention relates to the field of organic synthesis and medicinal chemistry and specifically relates to an alpha-hederagenin derivative with a structure as shown in a general formula I. The invention discloses a preparation method for the alpha-hederagenin derivative, drug compounds containing the alpha-hederagenin derivative and application thereof in tumor drug-resisting reversion.

The invention relates to a method for extracting chlorogenic acid and hederagenin from honeysuckle flower. The method is characterized by comprising the following steps of: smashing the honeysuckle flower; extracting with a 70-90 percent ethanol solution; recovering ethanol from an extracting solution under reduced pressure; adding water into a concentrated solution for dispersing; adding into a macroporous resin column for adsorbing; eluting with a 40-70 percent of ethanol solution; recovering ethanol from an eluent and adding n-butyl alcohol for extracting; recovering n-butyl alcohol; adjusting the pH of the concentrated solution to 4-7, and adding a biological enzyme for performing enzymolysis; concentrating a hydrolysate; and filtering to obtain a solid and a filtrate; and purifying the solid and the filtrate respectively to obtain a hederagenin product and a chlorogenic acid production. The method has simple process operation and high raw material utilization ratio, and is suitable for industrial production.

The invention discloses an fructus akebiae extract, which is prepared by a method of: taking an fructus akebiae medicinal material as a raw material, performing degreasing treatment first, then orderly performing ethanol extraction, ethyl acetate treatment and water saturated normal butanol extraction to obtain total saponin of fructus akebiae, and performing acid-containing ethanol degradation and purification treatment on the obtained total saponin to obtain the fructus akebiae extract, wherein the weight percentage of hederagenin in the fructus akebiae extract is not lower than 60 percent. The invention also discloses the method for preparing the fructus akebiae extract, a preparation and application thereof. The fructus akebiae extract has the advantages of less impurities, high content of active components, and scientific and reasonable steps; the preparation thereof is safe and effective and has reliable quality; and the fructus akebiae extract and the preparation thereof have good antidepression effect.

The invention belongs to the technical field of medicines, and in particular relates to hederagenin A-cyclopyrazine derivatives with novel structures and a preparation method of the hederagenin A-cyclopyrazine derivatives. The hederagenin A-cyclopyrazine derivatives with the novel structures have the structures as shown in the general formula I. The compounds disclosed by the invention have the same in-vivo drug resistance reversal activity as in vitro and can be directly administered in vivo. The invention further discloses a preparation method of the derivatives and the application of the derivatives to preparation of tumor drug resistance reversal agents directly used in vivo.

The invention provides a method for preparing sapogenin through chenopodium quinoa willdL seed coat and a separation and quantification method of the sapogenin, and belongs to the technical field of biological product processing. The method for preparing the sapogenin through the chenopodium quinoa willdL seed coat comprises the following steps that firstly, the chenopodium quinoa willdL seed coat, complex enzyme and deionized water are mixed and enzymolyzed to obtain enzymatic hydrolysate; then the enzymatic hydrolysate and ethyl alcohol are mixed, chenopodium quinoa willdL saponin in the enzymatic hydrolysate is extracted through ultrasonic waves, solid-liquid separation is conducted, and a chenopodium quinoa willdL saponin extracting solution is obtained; then the chenopodium quinoa willdL saponin extracting solution and hydrochloric acid are mixed and subjected to acidolysis to obtain acidolysis liquid; and finally, the acidolysis liquid is extracted through petroleum ether to obtain extract liquor, and a solvent in the extract liquor is removed through evaporation, and the sapogenin is obtained. According to the method, the chenopodium quinoa willdL seed coat serves as a raw material to prepare the sapogenin, the natural sapogenin raw material can be provided for a professional pharmaceutical factory, the comprehensive utilization rate and the economic added value of chenopodium quinoa willdL can further be increased, and reuse and sustainable development of resources are facilitated. The invention further provides a method for simultaneous separation and quantification of oleanolic acid and hederagenin in the chenopodium quinoa willdL seed coat through UPLC-MS.

The invention discloses a method for determining contents of effective components in Clematis chinensis Osbeck, which comprises the following steps of (1) preparing a reference solution; (2) preparing a test sample solution; and (3) precisely extracting the reference solution and the test sample solution respectively, injecting into a liquid chromatograph, and determining by an evaporative light-scattering detector to obtain the contents of effective components including oleanolic acid and hederagenin, wherein the chromatographic filler is selected from octadecylsilane chemically bonded silica, the mobile phase is selected from methanol-water-acetic acid-triethylamine with a volumetric ratio of (80-95):(5-20):(0.01-0.1):(0.01-0.1), and the theoretical plate number, calculated by oleanolic acid, is not less than 2,000. The method has simple operation and can accurately determine the contents of oleanolic acid and hederagenin in Clematis chinensis Osbeck.

The invention relates to the fields of organic synthesis and pharmaceutical chemistry, and particularly discloses novel-structure alpha-helexin derivatives. The invention also discloses a preparation method of the triterpene saponin derivatives, a pharmaceutical composition containing the derivatives, and application of the derivatives in resisting neoplastic diseases.

The invention discloses a new application of total aglycone of himalayan teasel roots and single-component hederagenin in medicaments preparing Alpha-glucosidase inhibitor; the medicaments preparing the Alpha-glucosidase inhibitor can be the total aglycone of himalayan teasel roots, the single-component hederagenin, or a compound containing the total aglycone of himalayan teasel roots and the single-component hederagenin, which all can be prepared into tablets, capsules, granules, injections and suspensions.

The invention relates to hederagenin-based facial milk cleanser. Each part of facial milk cleanser comprises the following components by percentage: 5.0% to 8.0% of glycerol, 4.0% to 6.0% of propylene glycol, 0.1% to 0.2% of oleyl alcohol, 1.5% to 2.0% of polyoxyethylene sorbitan mono-laurate, 0.5% to 1.2% of polyoxyethylene lauryl alcohol, 1.0% to 2.0% of hederagenin, 10.0% to 12.0% of ethanol, 0.1% to 0.5% of essence and distilled water in balancing amount. The application method of the hederagenin-based facial milk cleanser comprises the following steps: wetting the face by water; holding a proper amount of the hederagenin-based facial milk cleanser in the palm; adding a small amount of water to the hederagenin-based facial milk cleanser, and lathering; lightly circling the hederagenin-based facial milk cleanser over the face for 1 to 2 minutes; and cleansing with clean water. The hederagenin-based facial milk cleanser targeting on greasy skin is capable of generating fine, smooth and abundant lather and thoroughly cleansing the pores, so that the skin can be clean, smooth and grease-free after the administration; and the hederagenin-based facial milk cleanser is also capable of improving the moisture barrier effect of the skin and keeping the balance of water and grease.

The invention discloses a method for extracting, separating and purifying chemical components of walnut green seedcases and application of the chemical components. According to the method, 13 compounds are separated from the walnut green seedcases and respectively identified as 3,5-dimethoxy-4-hydroxy-benzoic acid-7-O-beta-D-glucoside (1), myricananin F (2), beta-sitosterol (3), oleanolic acid (4), walnut ketone (5), asiatic acid (6), hederagenin (7), beta-carotene (8), (4R)-4,8-dihydroxy-alpha-tetralone-4-O-beta-D-glucopyranoside (9), 3beta,23-dihydroxy-12-olefin-28-ursolic acid (10), ursolicacid (11), syringic acid (12) and Juglanoside B (13). After screening of anti-tumor activity in vitro, it is found that some compounds have certain growth inhibitory activity against cancer cells andcan be further used for preparing anticancer drugs.

The invention relates to application of hederagenin-3-O-arabinopyranoside (hederagenin-3-O-arabinopyranoside). The Hederagenin-3-O-arabinopyranoside is obtained by utilizing a chemical extraction separation method. The chemical compound structure of the hederagenin-3-O-arabinopyranoside is identified by utilizing physical constants and spectroscopy methods to carry out an antineoplastic pharmacological testing for the hederagenin-3-O-arabinopyranoside, a result shows that the hederagenin-3-O-arabinopyranoside has good effect on antineoplastic aspects ,especially has good effects on restraining human breast cancer cells, sarcoma cells, gastric carcinoma cells, hepatoma carcinoma cells and prostate cancer cells. The hederagenin-3-O-arabinopyranoside can be used for preparing medicines for curing breast cancer, solid tumor, gastric cancer, liver cancer and prostate cancer.

The invention relates to an extraction method of hederagenin, and in the method, Chinese medicinal material teasel root is used as a raw material. The method comprises the following steps: a, adding hydrochloric acid or sulphuric acid into a 30-55% ethanol solution to prepare a 1.5-4N hydrochloric acid or sulphuric acid ethanol mixed solution; b, hydrolyzing the crushed teasel root in the hydrochloric acid or sulphuric acid ethanol mixed solution in the step a, filtering, and washing insoluble residues with water until the insoluble residues are neutral; c, extracting the residues obtained in the step b with an ethanol solution in a refluxing condition to obtain ethanol extract; and d, filtering the ethanol extract obtained in the step c through an ultrafiltration membrane with molecular weight cutoff of 3,000-8,000Da to obtain permeate, filtering the permeate with a nano-filtration membrane with a molecular weight cutoff of 200-600Da to obtain concentrate, and drying the concentrate to obtain the hederagenin. The method is simple and convenient in operation and simple and short in steps, so that the extraction quality and the extraction rate can be greatly improved.

The invention discloses a preparation method for hederagenin and the salts thereof, comprising the following steps of: extracting Dipsacus asperoides via ethanol, recovering a solvent from the extracted solution at a reduced pressure, purifying via macroporous adsorption resin or extracting and purifying via n-butyl alcohol to obtain Dipsacus asperoides total saponin, performing alkaline hydrolysis and acid hydrolysis on the Dipsacus asperoides total saponin, and then crystallizing or refining via the macroporous adsorption resin to obtain high-purity hederagenin, and reacting the hederagenin with alkali to prepare the salts of the hederagenin finally. According to the invention, the raw materials are abundant in the source and low in price; the whole preparation process is free from the use of toxic reagents, safe and low-toxicity; the preparation process is simple, high in separation and purification efficiency, greatly improved in the purity and productivity of the products, suitable for industrialized production, easy to popularize and apply, and remarkable in pharmacologic action; and a new medicine source is provided for treatment and research on hyperlipidemia.

The invention relates to a process for extracting blood sugar reducing active saponin from cyclocarya paliurus. The invention adopts the technical scheme that the method comprises the following steps: putting dry cyclocarya paliurus leaves into a flask, extracting the leaves under the refluxing of 90 percent ethanol solution, then centrifuging or filtering the extract, and reclaiming the ethanol solvent under reduced pressure when the filtered solution is at 58 DEG C to obtain dry cyclocarya paliurus paste with the density of 1.15 grams per cubic centimeter; dissolving 1 gram of dry cyclocarya paliurus paste into 3 milliliters of distilled water, transferring the solution into a separating funnel, extracting by using petroleum ether to remove grease, extracting the solution by using ethyl ether, combining water phases, then extracting by using n-butanol, combining n-butanol solution, and concentrating the solution under reduced pressure till the solution is reduced; and dissolving the concentrated substance in the distilled water, filtering the solution, filling the solution on an HPD400 macroporous resin column, removing sugar impurities by using the distilled water, eluting the macroporous resin column by using 70 percent ethanol, collecting 70 percent ethanol elution, concentrating the elution under reduced pressure till the elution is dried so as to obtain hederagenin H, wherein the yield of the saponin is 1.258 percent through measurement. The yield of the hederagenin obtained by the method is higher.

The invention provides a method for preparing hederagenin from soapberries. The method comprises the steps that soapberry total saponin is extracted through an ethanol-water mixture solvent, hydrolysis is carried out and crystallization process purification is carried out to obtain the hederagenin. The method for preparing hederagenin is high in yield, simple in operation, mild in condition, low in cost, free of pollution and environmentally friendly. By means of the method for preparing hederagenin, high-purity hederagenin can be obtained, the production cost is lower compared with the prior art, the yield is greatly improved, the application prospect is wide, and the requirements of rapidly-developed medical industry can be met.

The invention discloses a pharmaceutical composition for treating optic atrophy and a preparation method thereof. The pharmaceutical composition is prepared from bark of Japanese spicebush, Szechwan-Yunnan sanicle herb, asarinin, genistin, and hederagenin according to a ratio; the pharmaceutical composition may be made into various forms of drug according to conventional pharmaceutical processes to treat optic atrophy significantly.

The invention discloses a hederagenin amide derivative which is N-(3-dimethylaminopropyl)-hederagenin-17-formamide (HGA). According to the hederagenin amide derivative, 3-dimethylamino propylamine is introduced at the 28th position of the hederagenin, the hederagenin and a drone form a hydrogen bond due to the existence of amino, so that the biological activity of the hederagenin is improved, and an anti-depression effect of the hederagenin is better, and furthermore, a lot of experiments prove that the N-(3-dimethylaminopropyl)-hederagenin-17-formamide also has a good effect in neuroprotection and anti-tumor. The hederagenin amide derivative shows that neuroplasticity and depression are closely related, and a BDNF (brain derived neurotrophic factor) has a certain relationship with depression and is beneficial for the nerve plasticity to recover. The invention also discloses a mechanism studying an HGA neuroprotective effect from the point of view of BDNF and neuroplasticity.

The invention provides a triterpenoid saponin compound extracted from clematis tangutica. The molecular formula of the triterpenoid saponin compound is C59H96O27. The chemical structure of the compound is determined as 3beta-O-[3-O-alpha-L-rhamnopyranosyl-(1->2)-alpha-L-arabinopyranoside]-21alpha-hydroxy-Chinese ivy-28-O-alpha-L-rhamnopyranosyl-(1->4)-beta-D-glucopyranose-(1->6)-beta-D-glucopyranose(21alpha-dydroxy-3beta-O-[3-O-alpha-L-rhamnopyranosyl-(1->2)-alpha-L-arabinopyran osyl]-hederagenin-28-O-alpha-L-rhamnopyranosyl-(1->4)-beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranoside) by adopting spectrum technologies such as a high-resolution mass spectrum, a two-dimensional nuclear magnetic resonance spectrum and the like and a chemical method. As proved by an in-vitro anti-myocardial ischemia active result, the compound plays a remarkable role in protecting myocardial injury induced by an anoxic / reoxygenation model. The invention provides a lead compound for treating myocardial ischemia diseases, and the triterpenoid saponin compound can become a new cardiovascular medicament.

Disclosed are compositions enriched with thymohydroquinone, further comprising of thymoquinone, hederagenin and / or α-hederin formulated by blending the active molecules isolated from the seeds of Nigella sativa. Also disclosed are novel processes for the isolation of bioactive components thymohydroquinone, thymoquinone from the seeds of Nigella sativa. A process for the isolation α-hederin and hederagenin from the spent material of Nigella sativa is also disclosed herein.

The present invention is a method for preparing triterpenoids such as 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester and derivatives thereof from oleanic acid, ursolic acid, betulinic acid, sumaresinolic acid or hederagenin.

The invention discloses application of hederagenin and glucoside thereof in preparing anti-virus medicines, and provides application of No.1-15 hederagenin or saponin in preparing anti-virus medicines. Proofed by experiment results, the No.1-15 hederagenin or saponin has obvious protection function on RSV (respiratory syncytial virus), HSV-I (herpes virus-I) and CVB3 (coxsackie B3) virus-infectedmice; the death protection rate (%) of the No.1-15 hederagenin or saponin on the RSV, HSV-I and CVB3 virus-infected mice is 35% or above; the life elongation rate (%) of the No.1-15 hederagenin or saponin on the RSV, HSV-I and CVB3 virus-infected mice is 50% or above, so that the No.1-15 hederagenin or saponin can be developed into the antivirus medicines.